Role of Immune Therapies for Myeloma
Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft-versus-host disease. Recent years have witnessed efforts to induce more selective immune responses via dendritic cell vaccines, autologous and engineered T-cell therapy, and immune checkpoint blockade. Optimizing these immunotherapeutic approaches, understanding how to best use them in combination, and determining how to integrate them with standard anti-myeloma therapy could provide the potential to alter the natural history of this disease.
This activity has been designed to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Describe the rationale for use of immunotherapy in treating multiple myeloma
- List the immunotherapeutic strategies currently being evaluated in clinical trials for treatment of multiple myeloma
- 1.00 Participation
- 1.00 Nurse
- 1.00 Physician